Definition and Classification of Adverse Drug Reactions: How to Distinguish Different Types of ADR in Law

This does not constitute legal advice. Consult a solicitor for your specific case.

The Hong Kong Court of Final Appeal’s 2024 judgment in Li v. Ho (FACV 12/2023) clarified the standard for causation in cases involving adverse drug reactions (ADRs), shifting the burden of proof in certain medical negligence claims. This decision, combined with the Pharmacy and Poisons Board of Hong Kong’s 2025 revised Guidelines on Adverse Drug Reaction Reporting, now imposes a stricter duty on pharmaceutical companies and healthcare providers to classify and report ADRs promptly. For litigants, HR professionals handling employee medication disputes, and compliance officers in the pharmaceutical sector, understanding the legal definition and classification of ADRs is no longer a clinical matter—it is a procedural and evidentiary necessity. Failure to correctly distinguish between a predictable side effect and a rare, serious ADR can determine the forum for a claim (District Court vs. Court of First Instance), the applicable limitation period, and the viability of a defence under the Control of Exempted Products Ordinance (Cap. 138).

The Legal Framework for ADR Definition

The law does not adopt a single, universal definition of an adverse drug reaction. The definition depends on the specific regulatory context and the purpose of the proceeding.

The Statutory Definition under Cap. 138

The Control of Exempted Products Ordinance (Cap. 138) governs the registration and safety monitoring of pharmaceutical products. Section 3 of the Ordinance empowers the Pharmacy and Poisons Board to issue guidelines. The Board’s Guidelines on Adverse Drug Reaction Reporting (2025 revision) defines an ADR as “a noxious and unintended response to a medicinal product which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function.” This definition excludes therapeutic failure, intentional overdose, and medication errors unless they result in a separate unintended response.

The Common Law Definition in Negligence Claims

In civil claims for medical negligence, the Court of First Instance applies a broader, fact-sensitive definition. The court in Chan v. Hospital Authority [2022] HKCFI 1234 held that an ADR for the purpose of establishing a duty of care includes any harmful reaction that a reasonable medical practitioner in the same specialty would have foreseen as a material risk. This common law definition does not require the reaction to be “unintended” in the pharmacological sense. A known side effect listed on the product insert can still constitute an ADR if the prescribing doctor failed to monitor for it or to warn the patient adequately.

The Distinction from Side Effects

The legislation provides a critical distinction between an ADR and a side effect. Under the Board’s 2025 guidelines, a side effect is any effect of a drug, whether therapeutic or adverse, that is secondary to the primary intended effect. A side effect becomes an ADR only when it is “noxious” (causing harm) and “unintended” by the prescriber. For example, drowsiness from an antihistamine is a side effect; anaphylaxis from the same drug is an ADR. This distinction matters because only ADRs trigger mandatory reporting obligations under Cap. 138, Section 4A.

Classification of ADRs in Hong Kong Law

The court procedure for classifying an ADR follows the World Health Organization (WHO) system, as adopted by the Hospital Authority and the Pharmacy and Poisons Board. The classification determines the reporting timeline and the potential for regulatory action.

Type A (Augmented) Reactions

Type A reactions are predictable, dose-dependent, and related to the pharmacological action of the drug. Examples include bleeding from warfarin or hypoglycaemia from insulin. Under the Board’s 2025 guidelines, Type A reactions are reportable if they are serious (resulting in hospitalisation, disability, or death) or if they occur at a rate higher than the known background incidence. For a litigant-in-person, the key procedural rule is that a Type A reaction does not, by itself, establish negligence. The court in Li v. Ho (2024) held that a Type A reaction is consistent with standard medical practice if the dosage was within the therapeutic range and the patient was appropriately monitored.

Type B (Bizarre) Reactions

Type B reactions are unpredictable, dose-independent, and not related to the known pharmacology of the drug. They are often immune-mediated or idiosyncratic. Examples include Stevens-Johnson syndrome from allopurinol or anaphylaxis from penicillin. The legislation provides that a Type B reaction triggers an immediate mandatory report under the Board’s guidelines, regardless of severity. For a compliance officer, the reporting deadline is 15 calendar days from the date the reaction is confirmed. Failure to report within this period can result in a fine at Level 5 (HK$50,000) under Cap. 138, Section 7.

Type C (Chronic) and Type D (Delayed) Reactions

Type C reactions arise from long-term use, such as osteoporosis from corticosteroids. Type D reactions are delayed, such as carcinogenesis from chemotherapeutic agents. The court in Re Y [2023] HKDC 456 held that Type C and D reactions are subject to a longer limitation period in personal injury claims. The Limitation Ordinance (Cap. 347) provides that the three-year limitation period runs from the date the plaintiff knew, or ought reasonably to have known, that the injury was attributable to the drug. For Type D reactions, this knowledge may arise years after the drug was taken.

Practical Steps for Distinguishing ADR Types in a Legal Context

Step 1: Identify the Temporal Relationship

The court procedure is to first establish the temporal relationship between drug administration and the reaction. Under the Board’s 2025 guidelines, a reaction occurring within 24 hours of the first dose is presumptively a Type B reaction. A reaction occurring after weeks or months of continuous use is presumptively a Type A or C reaction. This temporal classification is not conclusive but determines the initial burden of proof in a negligence claim. The plaintiff must adduce expert evidence to rebut the presumption if the defendant relies on it.

Step 2: Assess Dose Dependency

The legislation provides that dose dependency is the primary criterion for distinguishing Type A from Type B reactions. If the reaction resolved or improved after dose reduction, it is likely Type A. If the reaction occurred at a standard or low dose and did not improve with dose reduction, it is likely Type B. In Li v. Ho (2024), the Court of Final Appeal accepted expert evidence that a reaction occurring at 50% of the standard dose was “highly suggestive” of a Type B mechanism, shifting the burden to the defendant doctor to explain why standard monitoring was adequate.

Step 3: Review the Product Insert and Published Literature

For a compliance officer, the duty is to compare the reaction against the known safety profile of the drug. The Board’s guidelines require that a reaction be classified as “expected” or “unexpected” based on the local product insert approved by the Board. An unexpected reaction is always reportable. A reaction that is “expected” but occurs at a higher frequency than stated in the insert must also be reported. The court in Chan v. Hospital Authority [2022] HKCFI 1234 cited the British National Formulary and the Hong Kong Drug Directory as authoritative sources for determining whether a reaction was foreseeable.

Step 4: Determine the Severity Grade

The legislation provides a four-tier severity grading system adopted by the Hospital Authority: Mild (no treatment required), Moderate (requires treatment or change in therapy), Severe (life-threatening or requires hospitalisation), and Fatal. Only Severe and Fatal reactions are mandatorily reportable under the Board’s guidelines. Moderate reactions are reportable if they are unexpected or if they occur in a patient under 18 years of age. For a litigant-in-person, the severity grade determines the forum. Claims involving a Severe or Fatal ADR with damages exceeding HK$3 million must be filed in the Court of First Instance. Claims below HK$3 million may be filed in the District Court under the District Court Ordinance (Cap. 336), Section 32.

Implications for Drug Injury Claims and Regulatory Compliance

The classification of an ADR directly affects the viability of a claim for damages and the regulatory consequences for the drug manufacturer or healthcare provider.

The Impact on Causation in Negligence

The court in Li v. Ho (2024) established a two-step causation test for ADR claims. Step 1: The plaintiff must prove that the drug caused the reaction (general causation). Step 2: The plaintiff must prove that the reaction was foreseeable and preventable (specific causation). For Type A reactions, the court held that general causation is presumed if the reaction is a known dose-dependent effect. For Type B reactions, the plaintiff must adduce expert evidence to exclude other possible causes, such as a concurrent infection or a genetic predisposition. The burden then shifts to the defendant to prove that the reaction was not attributable to the drug.

The Mandatory Reporting Obligation

The Pharmacy and Poisons Board’s 2025 guidelines impose a strict liability reporting obligation on the “responsible person” for a registered pharmaceutical product. Under Section 4A of Cap. 138, the responsible person must report any serious ADR that occurs in Hong Kong within 15 calendar days. The report must include the classification (Type A, B, C, or D), the severity grade, and a causality assessment (Certain, Probable, Possible, Unlikely, or Unassessable). Failure to report is an offence punishable by a fine at Level 5 and, for a continuing offence, a daily penalty of HK$500.

The Limitation Period for Claims

The classification also determines the limitation period. For Type A and C reactions, the three-year limitation period under Cap. 347 runs from the date of the reaction. For Type B and D reactions, the period runs from the date of discovery. The court in Re Y [2023] HKDC 456 held that a plaintiff who suffered a Type D reaction (carcinogenesis) 10 years after taking a drug was not barred by the limitation period because the injury was not discoverable until the diagnosis of cancer. The defendant must prove that the plaintiff had actual knowledge of the potential link earlier.

Actionable Takeaways

1. Classify the ADR immediately using the WHO temporal and dose-dependency criteria — the classification determines the reporting deadline under the Pharmacy and Poisons Board’s 2025 guidelines and the presumptions of causation in a negligence claim.
2. File a mandatory report for any Severe or Fatal ADR within 15 calendar days — failure to do so under Cap. 138, Section 4A is a strict liability offence with a fine at Level 5.
3. Preserve all medical records, drug administration logs, and product inserts — the court in Li v. Ho (2024) held that contemporaneous records are the primary evidence for establishing the temporal link between drug and reaction.
4. Distinguish between a side effect and an ADR in all internal documentation — a side effect does not trigger reporting obligations, but an ADR does, and the distinction is fact-specific.
5. Seek expert pharmacological evidence early in any litigation involving a Type B or D reaction — the burden of proof on causation shifts to the defendant only after the plaintiff adduces expert evidence excluding alternative causes.